Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China-Reference-Cited by-同舟云学术

Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China

Published:2024-05-30 Issue:5 Volume:46 Page:1189-1199
ISSN:2210-7703
Container-title:International Journal of Clinical Pharmacy
language:en
Short-container-title:Int J Clin Pharm

Author:

Wei Jingxuan^ORCID,Xu Kai^ORCID,Lin Yingtao^ORCID,Liu Qiang^ORCID,Zhou Chongchong^ORCID,Zhang Pei^ORCID,Ma Rui^ORCID,Zhang Mengdie^ORCID,Zhang Lingli^ORCID,Li Xin^ORCID

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11096-024-01752-8.pdf

Reference55 articles.

1. The Global Cancer Observatory. Liver [EB/OL]. 2020. https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf. Accessed 05 Dec 2023.

2. Sung H, Ferlay J, Siegel R, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

3. Ju Dong Y, Pierre H, Gregory JG, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589–604. https://doi.org/10.1038/s41575-019-0186-y.

4. Ward EM, Sherman RL, Henley SJ, et al. Annual report to the nation on the status of cancer, featuring cancer in men and women age 20–49 years. J Natl Cancer Inst. 2019;111(12):1279–97. https://doi.org/10.1093/jnci/djz106.

5. The Global Cancer Observatory. China [EB/OL]. 2023. https://gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets.pdf. Accessed 04 Dec 2023.